<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01848470</url>
  </required_header>
  <id_info>
    <org_study_id>CG400549-1-02</org_study_id>
    <nct_id>NCT01848470</nct_id>
  </id_info>
  <brief_title>Multiple Ascending Doses Study of CG400549</brief_title>
  <official_title>Evaluation of Safety, Tolerability and Pharmacokinetic Characteristics of Multiple Ascending Doses of CG400549 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CrystalGenomics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CrystalGenomics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and tolerability of 3 multiple and
      escalating dose regimens of CG400549 administered orally in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, 3 cohorts study consisting of a randomised, double-blind, and
      placebo-controlled design.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>From Time the ICF is signed until Follow up Visit (15 days after study drug administration)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-tmax(h), Cmax (ng/mL), Auc (0-24), T1/2(h)</measure>
    <time_frame>Day1 and Day5</time_frame>
    <description>To determine the pharmacokinetics of CG400549 following oral administration of multiple ascending doses of CG400549 in healthy male subjects.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>E1. CG400549 640mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CG400549 640mg BID on Day 1-5 and QD on Day 6 in the fed-state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E2: CG400549 320mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CG400549 320mg QD on Day 1-5 in the fed-state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E3: CG400549 640mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CG400549 640mg QD on Day 1-5 in the fed-state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E4: CG400549 960mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CG400549 960mg QD on Day 1-5 in the fed-state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P1 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 640mg BID on Day 1-5 and QD on Day 6 in the fed-state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P2: Placebo 320mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 320mg QD on Day 1-5 in the fed-state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P3 Placebo 640mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 640mg QD on Day 1-5 in the fed-state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P4: Placebo 960mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 960mg QD on Day 1-5 in the fed-state.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CG400549 640mg</intervention_name>
    <description>multiple oral doses of 640 mg CG400549 (n=6) BID for 5 days (Days 1-5) and a final dose on Day 6 in the fed state</description>
    <arm_group_label>E1. CG400549 640mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CG400549 320 mg</intervention_name>
    <description>multiple oral doses of 320 mg CG400549 (n=6) QD for 5 days in the fed state</description>
    <arm_group_label>E2: CG400549 320mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CG400549 640 mg</intervention_name>
    <description>multiple oral doses of 640 mg CG400549 (n=6) QD for 5 days in the fed state</description>
    <arm_group_label>E3: CG400549 640mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CG400549 960 mg</intervention_name>
    <description>multiple oral doses of 960 mg CG400549 (n=6) QD for 5 days in the fed state</description>
    <arm_group_label>E4: CG400549 960mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 640mg</intervention_name>
    <description>multiple oral doses of 640 mg placebo (n=2) BID for 5 days (Days 1-5) and a final dose on Day 6 in the fed state</description>
    <arm_group_label>P1 Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 320mg</intervention_name>
    <description>multiple oral doses of 320 mg placebo (n=2) QD for 5 days in the fed state</description>
    <arm_group_label>P2: Placebo 320mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo 960 mg</intervention_name>
    <description>multiple oral doses of 960 mg placebo (n=2) QD for 5 days in the fed state</description>
    <arm_group_label>P3 Placebo 640mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 640mg</intervention_name>
    <description>multiple oral doses of 640 mg placebo (n=2) QD for 5 days in the fed state</description>
    <arm_group_label>P4: Placebo 960mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age:18-55 years, inclusive

          -  Body Mass Index :19-30 kg/m2, inclusive

          -  Sex:male

          -  Other criteria:healthy; non-smoking or smoking â‰¤ 10 cigarettes/day

        Exclusion Criteria:

          -  Evidence of clinically relevant pathology

          -  History of bacterial or viral infection requiring treatment with antibiotics or
             antivirals within 1 month of study

          -  Presence or history of esophageal or gastroduodenal ulceration within 1 month before
             screening.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seonggu Ro, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>CrystalGenomics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA International clinical center</name>
      <address>
        <city>Zuidlaren</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2013</study_first_submitted>
  <study_first_submitted_qc>May 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2013</study_first_posted>
  <last_update_submitted>May 3, 2013</last_update_submitted>
  <last_update_submitted_qc>May 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

